Back

Exploring the role of galectin-3 and pentraxin-3 as biomarkers in chronic coronary syndrome with atrial fibrillation: insights from an 87-patient cohort

30 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Pathophysiology in acute coronary syndromes (1) Biomarkers ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Alexandru Oancea

Grigore T. Popa University of Medicine and Pharmacy, Iasi (Romania)

7 More presentations in this session

Presentation thumbnail
SMC-derived foam cells regulate atherosclerotic plaque stability via the crosstalk between ECM remodeling and WNT signaling
Mx C. Li (Qingdao, CN)
Abstract Slides Video
Presentation thumbnail
High apo-CIII level correlates with poor lipid status, pro-inflammatory and fibrotic biomarker profile, and adverse cardiovascular outcome in patients with recent acute coronary syndrome
Ms S. Nilsson (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Gut microbiota-derived imidazole propionate is a novel marker of cardiometabolic risk in patients with coronary artery disease
Doctor F. Wenzl (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Cigarette smoking and release of the inflammatory chemokine CXCL10 (IP-10) after ST-elevation myocardial infarction
Doctor L. Spray (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
Hyperglycaemia-induced trained immunity alters monocyte function in type 2 diabetes patients after myocardial infarction
Doctor T. Kufazvinei (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology in acute coronary syndromes (1)

The Event

Event poster

ESC Congress 2025

30 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Pentraxin-3 as a novel biomarker to monitor disease progress and treatment response in patients with heart failure
thumbnail
Congress Session
Novel biomarkers in acute and chronic coronary syndromes
thumbnail
Congress Presentation
Biomarkers in atrial fibrillation: insights from the ACaSA study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources